Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Sep 15;206(6):969-73.
doi: 10.1093/infdis/jis434. Epub 2012 Jul 10.

Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection

Affiliations
Randomized Controlled Trial

Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection

Donald D Anthony et al. J Infect Dis. .

Abstract

Disease progression of human immunodeficiency virus type 1 (HIV-1) is associated with immune activation. Activation indices are higher during coinfection of hepatitis C virus (HCV) and HIV. The effect of immune activation on interferon α (IFN-α) therapy response is unknown. We evaluated soluble CD14 (sCD14) and natural killer (NK)-cell subsets at baseline, and during pegIFN-α2a/ribavirin therapy in HCV-HIV coinfection. The sCD14 level increased during therapy. Baseline sCD14 positively correlated with baseline HCV level and CD16(+)56(-) NK-cell frequency, and both sCD14 and CD16(+)56(-) NK cells correlated negatively with magnitude of HCV decline. IL28B genotype was associated with therapy response but not sCD14 or CD16(+)56(-) NK frequency. Markers of innate immune activation predict poor host response to IFN-α-based HCV therapy during HCV-HIV coinfection.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Plasma soluble CD14 (sCD14) increases during pegylated interferon-α/ribavirin (pegIFN/RBV) killer (NK)–cell frequency. A, Plasma sCD14 level was measured at baseline, week 12, and week 24 of pegIFN/RBV therapy (n = 19, all HCV genotypes). BC, Baseline plasma sCD14 level (B) and CD3–14-19-16+56 NK-cell frequency (C)in relation to week 4 (n = 14 for sCD14 and n = 19 for CD16+CD56 NK), week 12 (n = 14 for sCD14, and n = 20 for CD16+CD56 NK), and week 24 (n = 13 for sCD14 and n = 19 for CD16+CD56 NK) HCV genotype-1 viral decline magnitude.
Figure 2.
Figure 2.
Pairwise comparisons for hepatitis C virus (HCV) genotype 1 virologic response status. A, Plasma sCD14 at baseline (week 0) and week 12 is plotted by virologic response status (rapid virologic response [RVR], early virologic response [EVR], complete EVR [cEVR], and sustained virologic response [SVR]). B, Week 0 CD16+56 natural killer (NK) frequency by virologic response status. Box plots represent median, interquartile range, minimum, and maximum. P < .1 is shown.

References

    1. De Maria A, Moretta L. NK cell function in HIV-1 infection. Curr HIV Res. 2008;6:433–40. - PubMed
    1. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med. 2009;60:471–84. - PMC - PubMed
    1. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780–90. - PMC - PubMed
    1. Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol. 2010;135:12–25. - PubMed
    1. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141:1220–30. 1230 e1221–1223. - PMC - PubMed

Publication types

MeSH terms